Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

Table 2 Carfilzomib PK parameters and inferential PK statistics comparing carfilzomib exposure following IV administration of carfilzomib (PK-evaluable population)

Values presented as geometric mean (geometric CV%); T_max median (minimum–maximum is presented). Data in table excludes n = 1 cycle 2 day 1 outlier patient from the normal hepatic function group
AUC _0–inf area under the concentration time curve from time extrapolated to infinity, AUC _0–last area under the concentration time curve from time 0 to last concentration measurement, C _max maximum plasma concentration, T _max time to maximum plasma concentration
^an = 8
^bn = 12
^cn = 7
^dn = 6

ISSN: 2162-3619